EXTH-07. AN ANTISENSE OLIGONUCLEOTIDE AGAINST TUMOR MICROTUBES IN GLIOBLASTOMA AS A NEW THERAPEUTIC OPTION TO IMPROVE TUMOR SPECIFIC THERAPY

Abstract Glioblastomas are known to be highly therapy resistant tumors. The description of tumor microtubes (TMs) as long cellular protrusions that connect glioblastoma cells a network against all standard therapies advanced the basic biological understanding disease and offers new therapeutic target. An antisense oligonucleotide (ASO) production protein involved in formation function TMs was developed tested xenograft mouse model human cells. After implantation fluorescent under chronic cranial window establishment tumor, ASO treatment started with continuous micropump application directly into central nervous system (CNS) effects were observed two-photon microscope. Furthermore, co-treatment irradiation size well expression evaluated ex vivo. This led conclusion setup combined pump two photon microscopy is technically feasible tolerable. It possibility applying compounds CNS live longitudinal readouts. fluorescently tagged traced brain parenchyma over weeks proving high stability compound. In combination radiotherapy, animals treated active showed smaller than radiotherapy non-targeting ASO. targeted expressed less then receiving control extend correlated size. Hence, after successful ASOs other neurologic diseases need for better options patients, development an TM option translational potential.